December 31, 2020 Revelation Biosciences, Inc. Re: Global Health Agreement Ladies and Gentlemen:Letter Agreement • November 4th, 2021 • Petra Acquisition Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledNovember 4th, 2021 Company Industry JurisdictionThis global health letter agreement (“Global Health Agreement”) is entered into by and between Revelation Biosciences, Inc. a Delaware corporation (the “Company”) and AXA Prime Impact Master Fund I SCA SICAV-RAIF (the “Investor” or “AXA IM Impact Fund”) in connection with its commitment to purchase certain shares of the Company’s Series A Preferred Stock (the “Shares”) in accordance with the terms of that certain Series A Preferred Stock Purchase Agreement dated as of even date herewith (the “Purchase Agreement”), at a price of $6.36 per share (for a total of $3,999,994.80) (the “Investment”).
December 31, 2020 Revelation Biosciences, Inc. Re: Global Health Agreement Ladies and Gentlemen:Letter Agreement • September 20th, 2021 • Petra Acquisition Inc. • Blank checks • Delaware
Contract Type FiledSeptember 20th, 2021 Company Industry JurisdictionThis global health letter agreement (“Global Health Agreement”) is entered into by and between Revelation Biosciences, Inc. a Delaware corporation (the “Company”) and AXA Prime Impact Master Fund I SCA SICAV-RAIF (the “Investor” or “AXA IM Impact Fund”) in connection with its commitment to purchase certain shares of the Company’s Series A Preferred Stock (the “Shares”) in accordance with the terms of that certain Series A Preferred Stock Purchase Agreement dated as of even date herewith (the “Purchase Agreement”), at a price of $6.36 per share (for a total of $3,999,994.80) (the “Investment”).